Introduction
============

Non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (*EGFR*) mutations are extremely sensitive to the EGFR-targeting tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib \[[@mdw611-B1]\]. These three agents are established first-line treatment options in this setting; however, until recently, there was an absence of prospective randomised head-to-head comparisons to help guide treatment decisions.

To our knowledge, the recent randomised phase IIb LUX-Lung 7 trial was the first study to compare the irreversible ErbB family blocker, afatinib, with a reversible EGFR TKI, gefitinib, in treatment-naïve patients with advanced NSCLC harbouring a common *EGFR* mutation (exon 19 deletion/L858R) \[[@mdw611-B9]\]. In this trial, afatinib significantly improved progression-free survival \[PFS; hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.57‒0.95, *P* = 0.0165\], time-to-treatment failure (TTF; HR 0.73, 95% CI 0.58‒0.92, *P* = 0.0073) and objective response rate (ORR; 70% versus 56%; odds ratio 1.873, 95% CI 1.176--2.985, *P* = 0.0083) compared with gefitinib. Overall, afatinib was well tolerated, with a predictable and manageable adverse event (AE) profile. Treatment-related AEs were experienced in 97.5% and 96.2% of patients in the afatinib and gefitinib arms, respectively. The most frequent grade ≥3 treatment-related AEs were diarrhoea (12.5%), rash/acne (9.4%) and fatigue (5.6%) with afatinib and elevated liver enzymes (8.8%), rash/acne (3.1%) and interstitial lung disease (ILD) (1.9%) with gefitinib. There was one drug-related fatal AE; a case of hepatic and renal failure with gefitinib treatment. There was no difference in the drug discontinuation rate due to treatment-related AEs between afatinib and gefitinib.

Along with PFS and TTF, overall survival (OS) was a co-primary endpoint of LUX-Lung 7; however, OS data were immature at the time of the primary analysis. Here, we report the mature OS results, including prespecified subgroup analysis and post-hoc analysis of the impact of post-study treatment on OS.

Methods
=======

Study design and treatment
--------------------------

Full details on the trial design of LUX-Lung 7 have been published \[[@mdw611-B9]\]. LUX-Lung 7 was a multicentre, international, randomised, open-label phase IIb trial (64 sites; 13 countries). Eligible patients were aged ≥18 years with treatment-naïve pathologically confirmed stage IIIB/IV adenocarcinoma and a documented common activating *EGFR* mutation (exon 19 deletion/L858R). Patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, at least one measurable lesion \[Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\] and adequate organ function. Patients were randomised 1:1 to once-daily oral afatinib 40 mg or gefitinib 250 mg and were treated until disease progression, intolerable AEs or other reasons necessitating withdrawal. Treatment beyond radiological progression was allowed for patients deemed to be receiving continued clinical benefit by the treating physician.

The co-primary endpoints were PFS by independent central review, TTF (time from randomisation to the time of treatment discontinuation for any reason including disease progression, treatment toxicity, and death) and OS. ORR by independent central review was a secondary endpoint. AEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 (NCI CTCAE 3.0). Post-study treatments were provided at the physician's discretion and assessed retrospectively.

The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines as defined by the International Conference on Harmonization. All patients provided written informed consent.

Statistical plan
----------------

Three analysis timepoints were planned. The primary PFS/TTF analysis was planned after 250 PFS events and was previously published \[[@mdw611-B9]\]. The primary OS analysis (reported herein) was planned after approximately 213 OS events and a follow-up period of at least 32 months for patients still alive. The final analysis will be undertaken at study completion (when all patients have completed treatment, or 5 years since the last patient was entered, whichever occurs first).

All randomised patients were included in the primary assessment of OS, and updated analysis of PFS and TTF (intention-to-treat population). Safety analysis included all patients who received at least one dose of study drug. OS and PFS/TTF were analysed by a log-rank test stratified by *EGFR* mutation type and the presence of baseline brain metastases. A Cox proportional hazards model was used to calculate HRs and 95% CIs. Prespecified subgroups included *EGFR* mutation type (exon 19 deletion/L858R), baseline brain metastases (presence versus absence), ECOG PS (0 versus 1), sex, age (\<65 versus ≥65 years), ethnic origin (Asian versus non-Asian) and smoking history. ORR and disease control rate (DCR) were compared with a logistic regression model. All statistical testing was two sided at the nominal 5% significance level, with no adjustment for multiplicity. Data were analysed with SAS version 9.4.

Results
=======

Patients
--------

A total of 319 patients were randomised and treated with afatinib (*n* = 160) or gefitinib (*n* = 159). Baseline characteristics have been published and were similar between treatment groups \[[@mdw611-B9]\]. Two-hundred and twenty-six OS events had occurred at the data cut-off of 8 April 2016; 109 (68.1%) and 117 (73.6%) patients treated with afatinib and gefitinib, respectively, had died by this time. At the time of analysis, the median duration of treatment was 13.7 months (range: 0‒46.4) with afatinib and 11.5 months (range: 0.5‒48.7) with gefitinib. Forty (25.0%) and 21 (13.2%) patients were treated for \>24 months with afatinib and gefitinib, respectively. At data cut-off, 14 (8.8%) and 8 (5.0%) patients remained on treatment with afatinib and gefitinib.

Following discontinuation of study treatment, the majority of patients received at least one systematic anti-cancer therapy (72.6% and 76.8% in the afatinib and gefitinib arms, respectively; Table [1](#mdw611-T1){ref-type="table"}). Many patients also received third-line (43.8% and 55.0%), fourth-line (24.0% and 31.1%) and fifth-line therapies (13.0% and 19.2%, respectively). Fewer patients in the afatinib arm received a subsequent EGFR TKI than in the gefitinib arm (45.9% versus 55.6%); this imbalance was observed in both the *EGFR* exon 19 deletion (51.8% versus 59.8%) and L858R (38.1% versus 50.0%) subgroups. Twenty (13.7%) and 23 (15.2%) patients who discontinued study treatment in the afatinib and gefitinib arms received a third-generation EGFR TKI. Table 1Subsequent therapies in patients who discontinued study treatment, in the overall population and in *EGFR* mutation subgroupsTreatment, *n* (%)Overall populationExon 19 deletionL858R mutationAfatinib (*n* = 146)Gefitinib (*n* = 151)Afatinib (*n* = 83)Gefitinib (*n* = 87)Afatinib (*n* = 63)Gefitinib (*n* = 64)None38 (26.0)28 (18.5)20 (24.1)14 (16.1)18 (28.6)14 (21.9)Systemic anti-cancer therapy106 (72.6)116 (76.8)61 (73.5)69 (79.3)45 (71.4)47 (73.4)  Chemotherapy[^a^](#tblfn1){ref-type="table-fn"}84 (57.5)91 (60.3)48 (57.8)55 (63.2)36 (57.1)36 (56.3)  Platinum based70 (47.9)71 (47.0)40 (48.2)44 (50.6)30 (47.6)27 (42.2)EGFR TKI67 (45.9)84 (55.6)43 (51.8)52 (59.8)24 (38.1)32 (50.0)  EGFR TKI monotherapy63 (43.2)74 (49.0)39 (47.0)47 (54.0)24 (38.1)27 (42.2)  First-generation   Gefitinib22 (15.1)27 (17.9)11 (13.3)21 (24.1)11 (17.5)6 (9.4)   Erlotinib23 (15.8)30 (19.9)16 (19.3)21 (24.1)7 (11.1)9 (14.1)  Second-generation   Afatinib6 (4.1)12 (7.9)4 (4.8)8 (9.2)2 (3.2)4 (6.3)   Poziotinib0 (0.0)4 (2.6)0 (0.0)1 (1.1)0 (0.0)3 (4.7)  Third-generation   Osimertinib15 (10.3)17 (11.3)9 (10.8)11 (12.6)6 (9.5)6 (9.4)   Olmutinib5 (3.4)5 (3.3)5 (6.0)3 (3.4)0 (0.0)2 (3.1)  EGFR TKI-containing combination[^b^](#tblfn2){ref-type="table-fn"}7 (4.8)15 (9.9)5 (6.0)8 (9.2)2 (3.2)7 (10.9)Immune checkpoint inhibitor3 (2.1)4 (2.6)2 (2.4)4 (4.6)1 (1.6)0 (0.0)Radiotherapy26 (17.8)34 (22.5)16 (19.3)15 (17.2)10 (15.9)19 (29.7)[^1][^2][^3]

Overall survival
----------------

After a median follow-up of 42.6 months, median OS with afatinib versus gefitinib was 27.9 versus 24.5 months (HR, 0.86; 95% CI 0.66‒1.12; *P* = 0.2580; Figure [1](#mdw611-F1){ref-type="fig"}A). Figure 1Overall survival. Kaplan--Meier curve (A) and forest plot of pre-specified subgroup analyses (B). CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HR, hazard ratio.

OS with afatinib versus gefitinib was similar across prespecified subgroups of interest (Figure [1](#mdw611-F1){ref-type="fig"}B). There was no significant OS difference between afatinib and gefitinib in pre-planned subgroups that were used as stratification factors, i.e. baseline brain metastases (presence versus absence) and *EGFR* mutation type (exon 19 deletion versus L858R). Median OS with afatinib versus gefitinib in patients with exon 19 deletions (30.7 versus 26.4 months; HR 0.83, 95% CI 0.58‒1.17, *P* = 0.2841; Figure [2](#mdw611-F2){ref-type="fig"}A) and patients with the L858R mutation (25.0 versus 21.2 months; HR 0.91, 95% CI 0.62‒1.36, *P* = 0.6585; Figure [2](#mdw611-F2){ref-type="fig"}B) was generally consistent with the overall *EGFR* mutation-positive study population. There was no interaction between OS and patient subgroups, except for age based on the cut-offs of \<65 and ≥65 years (Figure [1](#mdw611-F1){ref-type="fig"}B). However, further post-hoc analysis demonstrated a consistent trend for OS benefit with afatinib independent of age group (no interaction observed at cut-offs of 60, 70 or 75 years). Similar median OS with afatinib was seen at cut-offs of 60, 65, 70 and 75 years ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Of note, subgroup sample sizes decreased with increasing age cut-off. Figure 2Overall survival in patients with common *EGFR* mutations. Patients with exon 19 deletion (A) and patients with L858R mutation (B). CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.

In a post-hoc analysis, median OS with afatinib versus gefitinib in patients who received a third-generation EGFR TKI following discontinuation of study treatment was 'not evaluable' versus 46.0 months (HR 0.51, 95% CI 0.17‒1.52, *P *= 0.22; Figure [3](#mdw611-F3){ref-type="fig"}). Figure 3Overall survival in patients subsequently treated with a third-generation EGFR TKI following discontinuation of study treatment. CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; TKIs, tyrosine kinase inhibitors.

Other efficacy endpoints
------------------------

Updated analysis of the co-primary endpoints showed similar findings to the primary analysis \[[@mdw611-B9]\]. PFS by independent review (median 11.0 versus 10.9 months; HR 0.74, 95% CI 0.57‒0.95, *P* = 0.0178; [supplementary Figure S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online) and TTF (median 13.7 versus 11.5 months; HR 0.75, 95% CI 0.60‒0.94, *P* = 0.0136; [supplementary Figure S3](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online) were significantly improved with afatinib versus gefitinib.

Updated ORR was also significantly higher with afatinib than with gefitinib \[72.5% versus 56.0%; odds ratio 2.121 (95% CI 1.32--3.40); *P* = 0.0018; [supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online\]. The DCR was 91.3% versus 87.4% (afatinib versus gefitinib; odds ratio 1.552, 95% CI 0.75--3.22, *P* = 0.2372).

Safety
------

The safety profiles of afatinib and gefitinib were virtually unchanged since the primary analysis \[[@mdw611-B9]\]. The frequency of all-cause grade ≥3 AEs was 56.9% and 53.5%, and of treatment-related grade ≥3 AEs was 31.3% and 19.5%, with afatinib and gefitinib, respectively ([supplementary Table S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). The most frequent treatment-related grade ≥3 AEs with afatinib were diarrhoea (13.1% versus 1.3%), rash/acne (9.4% versus 3.1%) and fatigue (5.6% versus 0%). The most frequent treatment-related grade ≥3 AEs with gefitinib were elevated alanine transaminase (8.2% versus 0%), rash/acne, elevated aspartate aminotransferase (2.5% versus 0%) and interstitial lung disease (1.9% versus 0%; [supplementary Table S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). There was one drug-related fatal AE; a case of hepatic and renal failure with gefitinib treatment. Rates of treatment discontinuations due to drug-related AEs remained equally low (6.3% each).

Discussion
==========

In this updated analysis of LUX-Lung 7, a 14% reduction in risk of death was observed in patients with *EGFR* mutation-positive NSCLC treated with first-line afatinib versus gefitinib, that corresponded to a numerical difference of 3.4 months in median OS, without reaching statistical significance. These findings were generally consistent across key patient subgroups, including those based on gender, ethnicity (Asian versus non-Asian), and *EGFR* mutation type (exon 19 deletion versus L858R). Although initial analyses suggested a potential interaction between OS and patient age, subsequent post-hoc analysis demonstrated no clear pattern of association, and similar median OS with afatinib was observed for patients aged \</≥60,\</≥65, \</≥70 and \</≥75 years. Afatinib conferred long-term survival in a high proportion of patients, with 24-month and 30-month survival rates of 60.9% and 48.0%, respectively. These frequencies were consistent with a previous global, phase III trial, which assessed afatinib versus cisplatin/pemetrexed in patients with NSCLC harbouring common *EGFR* mutations (LUX-Lung 3). In this study, 59.6% and 49.8% of afatinib-treated patients survived for at least 24 and 30 months, respectively \[[@mdw611-B10]\]. In the present study, as in the primary analysis, afatinib significantly improved PFS, TTF and ORR versus gefitinib. No unexpected AEs were observed and discontinuation rates due to treatment-related AEs remained equally low in both arms.

Despite being recognised as the first-line standard-of-care in patients with *EGFR* mutation-positive NSCLC, an enduring feature of randomised controlled trials of EGFR TKIs in this setting has been a lack of clear OS benefit, even against platinum-doublet chemotherapy. Across multiple phase III trials, neither erlotinib \[[@mdw611-B4], [@mdw611-B7], [@mdw611-B11]\] nor gefitinib \[[@mdw611-B12]\] has demonstrated statistically significant OS improvement against chemotherapy. Although afatinib did not significantly improve OS versus chemotherapy in the overall populations of the LUX-Lung 3 and LUX-Lung 6 trials, a significant improvement in OS was observed with afatinib in a prespecified sub-analysis of each trial, in patients with NSCLC harbouring exon 19 deletion mutations \[[@mdw611-B10]\]. In the current study, there was no significant difference in OS between afatinib and gefitinib in patients with NSCLC harbouring an exon 19 deletion. Emerging evidence suggests that first-generation and second-generation EGFR TKIs may be particularly active in NSCLC with exon 19 deletions compared with the L858R mutation \[[@mdw611-B15]\], but this is based on trials that used chemotherapy as a comparator rather than TKI versus TKI comparisons. Therefore, as any efficacy benefit with afatinib over gefitinib in LUX-Lung 7 would not necessarily be restricted to patients harbouring exon 19 deletions only, we claim that the choice of a TKI for an individual patient might not be based on *EGFR* mutational profile.

The rates of post-progression therapy observed in this trial were noticeably high. Around 75% of patients in both arms received at least one systemic anti-cancer therapy, and multiple lines of therapy were common (∼25% received at least four lines). This rate of post-progression therapy is somewhat higher than reported in most previous trials including *EGFR* mutation-positive patients treated with EGFR TKIs (66%‒68% in erlotinib trials \[[@mdw611-B4], [@mdw611-B7], [@mdw611-B11]\], 64%‒90% in gefitinib trials \[[@mdw611-B12], [@mdw611-B14], [@mdw611-B16]\] and 58%‒70% in afatinib trials \[[@mdw611-B5], [@mdw611-B6]\]. In LUX-Lung 7, there were slight imbalances in the number of patients who received a subsequent first- (30.8% and 37.7%) or second-generation (4.1% and 10.6%) EGFR TKI monotherapy in the afatinib and gefitinib arms, respectively, although the uptake of third-generation EGFR TKIs was similar (13.7% and 15.2%). Although there is a general paucity of prospective data assessing the effectiveness of sequencing of first- and second-generation EGFR TKIs, it is conceivable that these imbalances might have influenced OS. Previous studies, for example, indicate that afatinib therapy administered post-gefitinib/erlotinib \[[@mdw611-B17], [@mdw611-B18]\], or gefitinib rechallenge \[[@mdw611-B19]\] offer modest efficacy benefits.

Furthermore, the limited sample size may have impaired the power of the trial to address the differences in OS benefit between afatinib and gefitinib in clinical practice.

The primary OS analysis described herein fulfilled the protocol requirement in terms of the planned number of events and minimum follow-up time. However, at the time of writing, 29% of patients in LUX-Lung 7 were still alive and a final OS analysis is planned on study completion to assess the impact of a reduction in censored patients. It should be noted that LUX-Lung 7 was not powered for OS. As an exploratory phase IIb trial, no formal hypothesis was defined and sample size was based on controlling the width of the CI for the HR of PFS \[[@mdw611-B9]\]. Given the influence of non-NSCLC-related deaths and post-study treatments, OS requires larger sample sizes than PFS \[[@mdw611-B20]\].

Given the recent development of third-generation EGFR TKIs such as osimertinib and olmutinib, which are highly effective against T790M mutation-positive tumours \[[@mdw611-B21], [@mdw611-B22]\], improved understanding of, and screening for, mechanisms of acquired resistance to first-line EGFR-targeted agents will allow for the most appropriate and effective sequence of treatments for *EGFR* mutation-positive NSCLC patients. It is known that 50%‒60% of patients treated with erlotinib or gefitinib develop T790M-positive tumours following disease progression \[[@mdw611-B23], [@mdw611-B24]\]. Recent data indicate a similar frequency of T790M-mediated resistance in patients treated with first-line afatinib \[[@mdw611-B25]\]. Therefore, regardless of the choice of the first-line TKI in patients with *EGFR* mutation-positive NSCLC, similar numbers of patients are likely to benefit from a subsequent third-generation EGFR TKI. Although patient numbers are small, this assertion is supported by the current study. In both treatment arms, survival rates were striking in patients who received a subsequent third-generation EGFR TKI, with 3-year OS rates of up to 90%. These findings bode well for the strategy of sequential treatment with EGFR TKIs, which could potentially make *EGFR* mutation-positive NSCLC a chronic disease, at least in a subset of patients.

Other than the recent CTONG 0901 trial which compared gefitinib with erlotinib and found no difference in efficacy and safety \[[@mdw611-B26]\], LUX-Lung 7 is the only published trial to compare the first-line EGFR-targeted TKIs in patients with *EGFR* mutation-positive NSCLC \[although another head-to-head trial is currently comparing the second-generation TKI, dacomitinib, versus gefitinib (ARCHER-1050)\]. In summary, although LUX-Lung 7 was an exploratory phase IIb trial, we believe that the size of the trial (with 319 randomised patients it was as large as many phase III trials in the same setting) and the totality of the data being largely positive across multiple clinically relevant, independently assessed endpoints, suggests that afatinib may be a more effective treatment option than gefitinib in the first-line setting. Treatment-related AEs with afatinib were predictable, did not negatively impact health-related quality of life, and were largely manageable with tolerability-guided dose reductions such that the treatment discontinuation rate was the same as with gefitinib. We hypothesise that the efficacy benefits with afatinib reflect a broader mechanism of action compared with gefitinib.
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[^1]: Chemotherapy or chemotherapy-based combination.

[^2]: Including gefitinib (afatinib arm, *n* = 7; gefitinib arm, *n* = 11), erlotinib (*n* = 0; *n* = 5) and osimertinib (*n* = 0; *n* = 1).

[^3]: EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
